You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
岸邁生物1.2億美元C輪融資 鄭志剛跟投
阿思達克 03-23 12:13
專注於開發創新雙抗藥物的臨床階段生物製藥公司岸邁生物公布,完成1.2億美元C輪融資,由招銀國際CMBI及韓國未來資產基金Mirae Asset Financial Group共同領投,弘毅投資、魚鷹資管、燕創資本、Octagon Capital、新世界(00017.HK)執行副主席兼行政總裁鄭志剛,及上灣資本等投資人共同參與,現有投資機構如德誠資本、國投創新、夏爾巴投資和潛龍投資積極跟投。

公司表示,是次籌集的資金將用於推進岸邁生物的EMB-01、EMB-02和EMB-06正在進行的人體臨床研究,並拓展公司新型雙特異性抗體等生物藥的產品管線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account